NIPH Clinical Trials Search

Basic Information

Recruitment status
Health condition(s) or Problem(s) studied	Signs and Symptoms of Benign Prostatic Hyperplasia
Date of first enrollment	21/12/2011
Target sample size
Countries of recruitment
Study type	Interventional
Intervention(s)	investigational material(s) Generic name etc : Tadalafil INN of investigational material : Therapeutic category code : 259 Other agents for uro-genital and anal organ Dosage and Administration for Investigational material : Tadalafil 5mg or Placebo taken orally once-a-day

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum	>= 45age old
Age maximum	Not applicable
Gender	Male
Include criteria	The study population consists of men >_45 years of age who have BPH-LUTS for >6 months at Visit 1. Subjects are not to have taken finasteride for at least 3 months, dutasteride for at least 6 months, or any BPH, OAB, or ED therapy for at least 4 weeks prior to Visit 2. Subjects need to have a total IPSS of>_13.
Exclude criteria